A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Waverley Pharma synthesizes PARP-1 inhibitors
Waverley Pharma synthesizes PARP-1 inhibitors
Appointments and advancements for Feb. 24, 2026
Appointments and advancements for Feb. 24, 2026
Financings for Feb. 24, 2026
Financings for Feb. 24, 2026
In the clinic for Feb. 24, 2026
In the clinic for Feb. 24, 2026
Regulatory actions for Feb. 24, 2026
Regulatory actions for Feb. 24, 2026
Astellas and Vir in $1.3B deal for CD3 T-cell engager
Astellas and Vir in $1.3B deal for CD3 T-cell engager
Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies
Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies
Other news to note for Feb. 24, 2026
Other news to note for Feb. 24, 2026
Harbour Biomed spins out newco in $1.2B CTLA-4 deal
Harbour Biomed spins out newco in $1.2B CTLA-4 deal
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push
Appointments and advancements for Feb. 24, 2026
Appointments and advancements for Feb. 24, 2026
Financings for Feb. 24, 2026
Financings for Feb. 24, 2026
In the clinic for Feb. 24, 2026
In the clinic for Feb. 24, 2026
Other news to note for Feb. 24, 2026
Other news to note for Feb. 24, 2026
Regulatory actions for Feb. 24, 2026
Regulatory actions for Feb. 24, 2026
Appointments and advancements for Feb. 23, 2026
Appointments and advancements for Feb. 23, 2026
Financings for Feb. 23, 2026
Financings for Feb. 23, 2026
In the clinic for Feb. 23, 2026
In the clinic for Feb. 23, 2026
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page